Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19604 | 1.00 | ALDH1A1 (0.45) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 | |
| Hydrochloric Acid SCHEMBL6151027 | 0.98 | ALDH1A1 (0.44) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 | |
| Piperazine SCHEMBL27980522 | 0.98 | CXCR4 (0.47) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 | |
| SCHEMBL2911368 | 0.92 | CXCR4 (0.57) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 | |
| Hydrochloric Acid SCHEMBL4326310 | 0.90 | CXCR4 (0.55) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 | |
| SCHEMBL9059406 | 0.88 | ALDH1A1 (0.37) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 | |
| SCHEMBL18427338 | 0.87 | CA12 (0.44) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 | |
| SCHEMBL165923 | 0.86 | CXCR4 (0.50) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 | |
| SCHEMBL21848373 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 | |
| SCHEMBL2236609 | 0.85 | CXCR4 (0.52) | ALDH1A1MAPTPOLBSMN1; SMN2CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | claimed |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-2010496-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007119046-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | disclosed |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-2010496-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007119046-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | ALDH1A1 1650/4885MAPT 3289/4885POLB 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.